Oncology Drugs

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

We map digital grids and autonomous routes, but what about the biological networks that define half of humanity? An Indian brand is using ancient wisdom to build new infrastructure for women's health.

As corporate giants swallow local clinics, one alliance offers a lifeline. Here’s how AllyGPO and BioCareSD use AI and service to help doctors stay independent.

Millions suffer from Dry Eye Disease with few good options. A new clinical trial is now testing a drug tailored to a patient's DNA. Is this the end of trial-and-error?

FloBiotech and UCLA Health are betting on a new strategy against neurodegeneration: boosting the brain's own defenses. This alliance could redefine a field long plagued by failure.

A major study combining two powerful cancer drugs, KEYTRUDA and Trodelvy, has been halted, a setback for patients and a reality check for the industry.

Following its Ouro Medicines acquisition, Lakefront appoints veteran Eric Hedrick as CMO to drive its new immunology pipeline, signaling a bold transformation.

New data on elecoglipron, an oral pill with no food restrictions, shows major weight loss and A1C reduction, positioning AstraZeneca to disrupt the GLP-1 market.

Isabelle Fortier's appointment to the CCSA board brings frontline Arctic experience to national policy, a crucial move in Canada's evolving fight against the overdose crisis.

New data on Eli Lilly's oral GLP-1, orforglipron, shows superior results over rivals, promising a new era for millions of needle-averse patients.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

As dementia costs Ontario $30 billion annually, a new task force is not just another committee. It's a strategic blueprint for dismantling a broken system.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

As return-to-office mandates clash with the needs of 5 million Canadians with migraine, the economic toll of inaction is mounting for employers.

New research shows 'Food is Medicine' programs thrive when paired with human coaching, offering a potent, scalable model for tackling chronic disease.

Johnson & Johnson's acquisition of Firefly Bio for $1 billion signals a major push into degrader antibody conjugates, a new frontier for treating KRAS cancers.

Eikon Therapeutics adds a consumer goods giant to its board, a move signaling a strategic pivot from pure science to global commercialization.